By December 31, 1995, in the United States, a cumulative total of 513,846
AIDS cases and 310,849 deaths due to AIDS had been reported to the Centers
for Disease Control (CDC). It is estimated that over 4.4 million cases
of AIDS have occurred worldwide and over 20 million people have been
infected with the virus since the beginning of the epidemic. Up to 65%
of HIV-positive patients currently develop one of two main neoplasms identified
as AIDS-related tumors: Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma
The incidence of the established HIV-related malignancies will continue
to rise as the number of infected patients increases. As life expectancies
of HIV-infected patients lengthen, they will also go on to develop common
non-HIV-related malignancies, such as colon, prostate, and lung cancer.[3,5]
Thus, issues related to the appropriate management of these illnesses will
increase in importance. Other virally initiated malignancies with longer
latency periods between oncogenic transformation and clinical appearance
may also emerge in this population. Increased frequencies of such diseases
as cervical and anal dysplasia, anal carcinoma, and Hodgkin's disease have
already been reported in the setting of HIV disease.[6,7]
As details of the life cycle of the HIV virus are better understood,
it has become clear that the so-called latent period between initial infection
and the development of clinical symptoms is a time of continuous viral
replication and gradual destruction of critical aspects of the immune system
in the large majority of infected patients. Little information has been
gathered or released on the impact of current oncologic therapies on the
course of HIV replication and progression in patients with cancer and AIDS.[9,10]
Radiation therapy has a well-known immunosuppressive effect that has
been utilized therapeutically to prevent graft rejection in organ transplantation.[11,12]
Total lymphoid irradiation, in conjunction with the use of antiretroviral
therapies, has been suggested as a potential method for reducing the total
body load of HIV-infected cells.[12,13] It is not yet clear, however, whether
or not the clinical use of radiation results in an increase in HIV replication
Elegant studies of HIV replication in vitro revealed that both ultraviolet
and ionizing radiation increased binding of the transcription factor nuclear
factor-kappa-B to the promotor element of the integrated HIV genome of
HIVcat/HeLa cells. Unlike ultraviolet radiation, ionizing radiation
alone did not cause an immediate increase in HIV gene transcription. After
a period of several days from the time of exposure, however, rising levels
of HIV-cat gene expression were observed, as compared with unirradiated
controls. A separate study of the impact of 50 cGy of ionizing radiation
on HIV-infected mononuclear cells showed a substantial rise in p24 antigen
levels at 7 days after exposure, supporting the idea that ionizing
radiation may trigger enhanced HIV replication.
The development of a rational strategy for the optimal integration of
radiation therapy into the management of malignancies in HIV-infected patients
is critical. By analyzing the patient's past infectious history, known
duration of disease (time since seroconversion), immune status (indicators
such as CD4 count, trend of CD4 decline), history of antiretroviral use
(monotherapy vs combination therapy, specific nucleoside and nonnucleoside
reverse transcriptase inhibitors, protease inhibitors), and viral burden,[16,17]
the treating physician can get an idea of the rapidity of decline of the
overall immune system and a rough estimate of the patient's expected life
Prior to the introduction of the protease inhibitors, the average life
expectancy of an HIV-infected person in the United States was 7 to 11 years
after seroconversion and approximately 1.5 years after the diagnosis
of AIDS. During these periods, the quality of the patient's life can degenerate
considerably due to undertreated or overtreated malignancies. With the
proliferation of new antiviral agents, such as the protease inhibitors
and nonnucleoside analog reverse transcriptase inhibitors, the life expectancy
of these patients should increase, leaving the clinician with the dilemma
of recommending the best oncologic intervention for patients who develop
any malignancy. For example, a 50-year old HIV-positive patient with stage
B2 prostate cancer, a CD4 count of 550 cells/mm³, and no prior infections
should not be managed in the same way as a similar man with a CD4 count
of less than 10 cells/mm³ and a history of two bouts of Pneumocystis
and cryptococcal meningitis. But what about a man with a CD4 count of 150
cells/mm³, no prior antiretroviral therapy, and one episode of Pneumocystis
pneumonia? Therapeutic nihilism is not justifiable in this last case,[16,17]
as there is a reasonable chance that this patient would live long enough
to succumb from progressive prostate cancer rather than from AIDS.
Also, treatment intent (palliative vs curative) must be clear from the
onset of treatment. If palliative, a reasonable estimation must be made
of the expected length of time that symptom control may be required to
ensure maximal quality of life. If curative, the aggressiveness of the
approach must be weighed against the risk of further damaging the immune
system in the presence of HIV.
The use of systemic chemotherapy or extensive radiation is a major stress
that may redirect critical immune resources from maintaining a balance
with the prime offender, HIV, allowing a rapid increase in overall viral
burden. Initiation of antiretroviral therapy (preferably in combination
form) and appropriate infection prophylaxis should be strongly considered
for patients who have not been previously treated with such agents or have
received minimal therapy.[9,10,16]
In a case-control review of patients with HIV disease, patients with
systemic lymphoma were matched with patients without lymphoma (with similar
CD4 levels and no prior opportunistic infections). Exposure of the
first group to systemic chemotherapy resulted in a twofold increase in
the incidence of AIDS-defining events during and after the chemotherapy
period. CD4 and CD8 counts fell and viral loads increased during chemotherapy,
and CD4 counts remained at a depressed level for up to a year after the
end of chemotherapy.
The most appropriate antiretroviral program for patients with malignancies
and HIV disease has not been established.[10,16] Although combination programs,
including protease inhibitors and reverse transcriptase inhibitors, seem
to show the most benefit for previously untreated patients, certain constraints
must be kept in mind relative to the oncologic regimen. First, drugs should
be selected that do not have additive toxicities to those expected with
the anticancer agents used. Given the myelosuppression expected with radiation
fields encompassing large amounts of bone marrow or with systemic agents,
such as cisplatin (Platinol) and the alkylators, antiretroviral agents
with a significant risk of myelosuppression, such as zidovudine (Retrovir),
should be bypassed in favor of others with less myelosuppression, such
as didanosine (Videx).
Also, drugs associated with a risk of neuropathy (didanosine, stavudine
[Zerit], or zalcitabine [Hivid]) should be avoided if extensive nerve or
central nervous system (CNS) radiation is planned. Also, the radiation
oncologist should be aware that the protease inhibitors alter the P450
enzyme system, and thus, can affect the metabolism of chemotherapeutic
agents (taxanes, vinca alkaloids, anthracyclines, etoposide [VePesid])
and adjuvant medications routinely prescribed during radiation therapy
(meperidine, benzodiazepines, terfenadine [Seldane], and a host of others).
Whether or not any of the antiretroviral medications currently in use or
under development has radiation-sensitizing properties remains to be seen.
Anti-infectious prophylaxis regimens are well-described for patients
with HIV disease, and improve the life expectancy of such patients.
In general, prophylactic measures are not initiated until a patient's CD4
count drops below 200 cells/mm³. However, due to the fact that radiotherapy
or chemotherapy may result in a sudden decline in the CD4 count, such prophylaxis
should be considered at an earlier level. Prevention of Pneumocystis
carinii and toxoplasmosis with trimethoprim- sulfamethoxazole, Mycobacterium
avium-intracellulare with rifabutin (Mycobutin), and streptococcal
pneumonia with the pneumococcal vaccine should be seriously considered.
1. HIV/AIDS Surveillance Report. US Department of Health and Human Services,
Public Health Service, Centers for Disease Control and Prevention, 1996.
2. Global Programme on AIDS Report. World Health Organization, 1995.
3. Katz MH, Hessol NA, Buchbinder SP, et al: Temporal trends of opportunistic
infections and malignancies in homosexual men with AIDS. J Infect Dis 170:198-202,
4. Levine AM: AIDS-related malignancies: The emerging epidemic. J Natl
Cancer Inst 85:1382-1397, 1993.
5. Saah AJ, Hoover DR, He Y, et al: Factors influencing survival after
AIDS: Report from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune
Defic Syndr 7:287-295, 1994.
6. Melbye M, Cote TR, Kessler L, et al: High incidence of anal cancer
among AIDS patients: The AIDS/Cancer Working Group. Lancet 343:636-639,
7. Errante D, Zagonel V, Vaccher E, et al: Hodgkin's disease in patients
with HIV infection and in the general population: Comparison of clinicopathological
features and survival. Ann Oncol 2:37-40, 1994.
8. Folks TM, Hart CE: The life cycle of human immunodeficiency virus
type 1, in DeVita VT, Hellman S, Rosenberg SA, (eds): AIDS Etiology, Diagnosis,
Treatment and Prevention 1997, pp 29-44. Philadelphia, Lippincott-Raven,
9. Levine AM,Tulpule A, Espina B, et al: Low dose methotrexate, bleomycin,
doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine
in patients with acquired immunodeficiency syndrome-related lymphoma: Effect
on human immunodeficiency virus and serum interleukin-6 levels over time.
Cancer 78:517-526, 1996.
10. Sparano JA, Sarta C: Infection prophylaxis and antiretroviral therapy
in patients with HIV infection and malignancy. Current Opin Oncol 8:392-399,
11. Madden BP, Backhouse L, McClosky D, et al: Total lymphoid irradiation
as rescue therapy after heart transplantation. J Heart Lung Transplant
12. Fultz PN, Schwiebert RS, Su L, et al: Effects of total lymphoid
irradiation on SIV-infected macaques. AIDS Res Hum Retrovir 11:1517-1527,
13. McCune JM: Viral latency in HIV disease. Cell 82:183-188, 1995.
14. Valerie K, Laster WS, Kirkham JC, et al: Ionizing radiation activates
nuclear factor kappa B but fails to produce an increase in human immunodeficiency
virus gene expression in stably transfected human cells. Biochemistry 34:15768-15776,
15. Xu Y, Conway B, Montaner JS, et al: Effect of low-dose gamma radiation
of HIV replication in human peripheral blood mononuclear cells. Photochem
Photobiol 64:238-241, 1996.
16. Carpenter CC, Fischl MA, Hammer SM, et al: Antiretroviral therapy
for HIV infection in 1996: Recommendations of an international panel. International
AIDS Society-USA. JAMA 276:146-154, 1996.
17. Katzenstein DA, Hammer SM, Hughes MD, et al: The relation of virologic
and immunologic markers to clinical outcomes after nucleoside therapy in
HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl
J Med 335:1091-1098, 1996.
18. Coombs RW: HIV-1 burden as a marker of disease progression and clinical
response to therapy in AIDS. Clin Lab Med 14:301-311, 1994.
19. Phair JP: Estimating prognosis in HIV-1 infection (editorial). Ann
Intern Med 118:742-744, 1993.
20. Klatt EC, Nichols L, Noguchi TT: Evolving trends revealed by autopsies
of patients with the acquired immunodeficiency syndrome: 565 autopsies
in adults with the acquired immunodeficiency syndrome, Los Angeles, Calif,
1992-1993. Arch Pathol Lab Med 118:884-890, 1994.
21. Peterman TA, Jaffe HW, Beral V: Epidemiologic clues to the etiology
of Kaposi's sarcoma (editorial). AIDS 7:605-611, 1993.
22. Tappero JW, Conant MA, Wolfe SF, et al: Kaposi's sarcoma: Epidemiology,
pathogenesis, histology, clinical spectrum, staging criteria and therapy.
J Am Acad Dermatol 28:371-395, 1993.
23. Meyer JL: Whole-lung irradiation for Kaposi's sarcoma. Am J Clin
Oncol 16: 372-376, 1993.
24. Pantaleo G, Menzo S, Vaccarezza M, et al: Studies in subjects with
long-term nonprogressive human immunodeficiency virus infection. N Engl
J Med 332:209-216, 1995.
25. Fischl MA, Stanley K, Collier AC, et al: Combination and monotherapy
with zidovudine and zalcitabine in patients with advanced HIV disease:
The NIAID AIDS Clinical Trials Group. Ann Intern Med 122:24-32, 1995.
26. Lau RK, Hill A, Jenkins P, et al: Eight year prospective study of
HIV infection in a cohort of homosexual men--clinical progression, immunological
and virological markers. Int J Std AIDS 3:261-266, 1992.
27. Boudreaux AA, Smith LL, Cosby CD, et al: Intralesional vinblastine
for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency
syndrome: A clinical trial to evaluate efficacy and discomfort associated
with infection. J Am Acad Dermatol 28:61-65, 1993.
28. Northfelt DW: Treatment of Kaposi's Sarcoma: Current guidelines
and future perspectives. Drugs 48:569-582, 1994.
29. Bernstein ZP, Porter MM, Gould M, et al: Prolonged administration
of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy
results in selective expansion of innate immune effectors without significant
clinical toxicity. Blood 86:3287-3294, 1995.
30. McNamee D: Beta-hCG inhibits Kaposi's sarcoma. Lancet 345:1169,
31. Fife K, Bower M: Recent insights into the pathogenesis of Kaposi's
Sarcoma. Br J Cancer 73:1317-1322, 1996.
32. Formenti SC, Chak L, Gill P, et al: Increased radiosensitivity of
normal tissue fibroblasts in patients with acquired immunodeficiency syndrome
(AIDS) and with Kaposi's Sarcoma. Int J Radiat Biol 68:411-412, 1995.
33. Gao SJ, Kingsley L, Hoover DR, et al: Seroconversion to antibodies
against Kaposi's Sarcoma-associated herpesvirus-related latent nuclear
antigens before the development of Kaposi's Sarcoma. N Engl J Med 335:233-241,
34. Chang Y, Cesarman E, Pessin MS, et al: Identification of herpesvirus-like
DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869,
35. Piedbois P, Frikha H, Martin L, et al: Radiotherapy in the management
of epidemic Kaposi's Sarcoma. Int J Radiat Oncol Biol Phys 30:1207-1211,
36. Le BJ, Frikha H, Piedbois P, et al: Radiotherapy in the management
of epidemic Kaposi's Sarcoma of the oral cavity, the eyelid and the genitals.
Radiother Oncol 30:263-266, 1994.
37. Cooper JS, Fried PR: Toxicity of oral radiotherapy in patients with
acquired immunodeficiency syndrome. Arch Otolaryngol Head Neck Surg 113:327-328,
38. Holland JM, Swift PS: Tolerance of patients with human immunodeficiency
virus and anal carcinoma to treatment with combined chemotherapy and radiation
therapy. Radiology 193:251-254, 1994.
39. Piccinno R, Caccialanza M, Cusini M: Role of radiotherapy in the
treatment of epidemic Kaposi's Sarcoma: Experience with sixty-five cases.
J Am Acad Dermatol 32:1000-1003, 1995.
40. Berson AM, Quivey JM, Harris JW, et al: Radiation therapy for AIDS-related
Kaposi's Sarcoma. Int J Radiat Oncol Biol Phys 19:569-575, 1990.
41. Cooper JS, Fried PR: Defining the role of radiation therapy in the
management of epidemic Kaposi's Sarcoma. Int J Radiat Oncol Biol Phys 13:35-39,
42. de Wit R, Danner SA, Bakker PJ, et al: Combined zidovudine and interferon-alpha
treatment in patients with AIDS-associated Kaposi's Sarcoma. J Intern Med
43. Ghabrial R, Quivey JM, Dunn JJ, et al: Radiation therapy of acquired
immunodeficiency syndrome-related Kaposi's Sarcoma of the eyelids and conjunctiva.
Arch Ophthalmol 110:1423-1426, 1992.
44. Stelzer KJ, Griffin TW: A randomized prospective trial of radiation
therapy for AIDS-associated Kaposi's Sarcoma. Int J Radiat Oncol Biol Phys
45. Brunt AM, Phillips RH: Strontium-90 for conjunctival AIDS-related
Kaposi's sarcoma: the first case report. Clin Oncol (R Coll Radiol) 2:118-119,
46. Vapnek JM, Quivey JM, Carroll PR: Acquired immunodeficiency syndrome-related
Kaposi's sarcoma of the male genitalia: Management with radiation therapy.
J Urol 146:333-336, 1991.
47. Nemechek PM, Corder MC: Radiation recall associated with vinblastine
in a patient treated for Kaposi Sarcoma related to acquired immune deficiency
syndrome. Cancer 70:1605-1606, 1992.
48. Stelzer KJ, Griffin TW, Koh WJ: Radiation recall skin toxicity with
bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency
syndrome. Cancer 71:1322-1325, 1993.
49. Silverman SJ: Oral cancer education and HIV-associated malignancies.
J Cancer Education 9:152-154, 1994.
50. Macklis RM: Atypical radiation toxicity in patients with classical
Kaposi's Sarcoma. Tumori 77:491-495, 1991.
51. Miller RF, Tomlinson MC, Cottrill CP, et al: Bronchopulmonary Kaposi's
Sarcoma in patients with AIDS. Thorax 47:721-725, 1992.
52. Xu Y, Conway B, Montaner JS, et al: Effect of low-dose gamma radiation
of HIV replication in human peripheral blood mononuclear cells. Photochem
Photobiol 64:238-241, 1996.
53. Costleigh BJ, Miyamoto CT, Micaily B, et al: Heightened sensitivity
of the esophagus to radiation in a patient with AIDS. Am J Gastroenterol
54. Rabkin CS, Biggar RJ, Baptiste MS, et al: Cancer incidence trends
in women at high risk of human immunodeficiency virus (HIV) infection.
Int J Cancer 55:208-212, 1993.
55. Gail MH, Pluda JM, Rabkin CS, et al: Projections of the incidence
of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome.
J Natl Cancer Inst 83:695-701, 1991.
56. Rabkin CS, Hilgartner MW, Hedberg KW, et al: Incidence of lymphomas
and other cancers in HIV-infected and HIV-uninfected patients with hemophilia.
JAMA 267:1090-1094, 1992.
57. Kaplan LD: HIV-associated lymphoma. AIDS Clin Rev 94:145-166, 1993.
58. Herndier BG, Kaplan LD, McGrath MS: Pathogenesis of AIDS lymphomas.
AIDS 8:1025-1049, 1994.
59. Levine AM: AIDS-associated malignant lymphoma. Med Clin North Am
76: 253-268, 1992.
60. Kaplan LD, Shiramizu B, Herndier B, et al: Influence of molecular
characteristics on clinical outcome in human immunodeficiency virus-associated
non-Hodgkin's lymphoma: Identification of a subgroup with favorable clinical
outcome. Blood 85:1727-1735, 1995.
61. Kaplan L, Straus D, Testa M et al: Randomized trial of standard
dose m-BACOD with GM-CSF vs reduced dose m-BACOD for systemic related lymphoma
(abstract). Proc Am Assoc Clin Oncol 14:818, 1995.
62. Kaplan LD, Abrams DI, Feigal E, et al: AIDS-associated non-Hodgkin's
lymphoma in San Francisco. JAMA 261:719-724, 1989.
63. Freeman CR, Shustik C, Brisson ML, et al: Primary malignant lymphoma
of the central nervous system. Cancer 58:1106-1111, 1986.
64. Ling SM, Roach Mr, Larson DA, et al: Radiotherapy of primary central
nervous system lymphoma in patients with and without human immunodeficiency
virus: Ten years of treatment experience at the University of California
San Francisco. Cancer 73:2570-2582, 1994.
65. Shiramizu B, McGrath MS: Molecular pathogenesis of AIDS-associated
non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 5:323-330, 1991.
66. Baumgartner JE, Rachlin JR, Beckstead JH, et al: Primary central
nervous system lymphomas: Natural history and response to radiation therapy
in 55 patients with acquired immunodeficiency syndrome. J Neurosurg 73:206-211,
67. Forsyth PA, Yahalom J, DeAngelis LM: Combined-modality therapy in
the treatment of primary central nervous system lymphoma in AIDS. Neurology
68. From the Centers for Disease Control and Prevention: 1993 revised
classification system for HIV infection and expanded surveillance case
definition for AIDS among adolescents and adults. JAMA 269:729-730, 1993.
69. Rabkin CS, Yellin F: Cancer incidence in a population with a high
prevalence of infection with human immunodeficiency virus type 1. J Natl
Cancer Inst 86:1711-1716, 1994.
70. From the Centers for Disease Control. Risk for cervical disease
in HIV-infected women--New York City. JAMA 265:23-24, 1991.
71. Williams AB, Darragh TM, Vranizan K, et al: Anal and cervical human
papillomavirus infection and risk of anal and cervical epithelial abnormalities
in human immunodeficiency virus-infected women. Obstet Gynecol 83:205-211,
72. Tweddel G, Heller P, Cunnane M, et al: The correlation between HIV
seropositivity, cervical dysplasia, and HPV subtypes 6/11, 16/18, 31/33/35.
Gynecol Oncol 52:161-164, 1994.
73. Mandelblatt JS, Fahs M, Garibaldi K, et al: Association between
HIV infection and cervical neoplasia: implications for clinical care of
women at risk for both conditions. AIDS 6:173-178, 1992.
74. Maiman M, Fruchter RG, Guy L, et al: Human immunodeficiency virus
infection and invasive cervical carcinoma. Cancer 71:402-406, 1993.
75. Mueller BU, Pizzo PA: Cancer in children with primary or secondary
immunodeficiencies. J Pediat 126:1-10, 1995.
76. Spanos WJ, Clery M, Perez CA, et al: Late effect of multiple daily
fraction palliation schedule for advanced pelvic malignancies (RTOG 8502).
Int J Radiat Oncol Biol Phys 29:961-967, 1994.
77. Melbye M, Rabkin C, Frisch M, et al: Changing patterns of anal cancer
incidence in the United States, 1940-1989. Am J Epidemiol 139:772-780,
78. Northfelt DW, Swift PS, Palefsky JM: Anal dysplasia: Pathogenesis,
diagnosis and management, in Krown SE, von Roenn JH, (eds): Hematologic
and Oncologic Aspects of HIV Infection, pp 1177-1188. Hematology Oncology
Clinics of North America. Philadelphia, WB Saunders, 1996.
79. Flam MS, John MJ, Peters T et al: Radiation and 5-fluorouracil vs.
radiation, 5FU, mitomycin-C in the treatment of anal canal carcinoma: Preliminary
results of a phase III randomized RTOG/ECOG intergroup trial. Proc Am Soc
Clin Oncol 12:192, 1993.
80. Biggar RJ, Curtis RE, Cote TR, et al: Risk of other cancers following
Kaposi's sarcoma: relation to acquired immunodeficiency syndrome. Am J
Epidemiol 139:362-368, 1994.
81. Hessol NA, Katz MH, Liu JY, et al: Increased incidence of Hodgkin
disease in homosexual men with HIV infection. Ann Intern Med 117:309-311,
82. Medeiros LJ, Greiner TC: Hodgkin's disease. Cancer 357-369, 1995.
83. Hammer SM, Katzenstein DA, Highes MD, et al: A trila comparing nucleoside
monotherapy with combination therapy in HIV-infected adults with CD4 counts
from 200 to 500 per cubic millimeter. N Engl J Med 335:1081-1090, 1996.